+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

France - Healthcare, Regulatory and Reimbursement Landscape

  • ID: 2559792
  • Report
  • June 2021
  • Region: France
  • 171 Pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

This report presents valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by the publisher’s team of industry experts.

France is the second largest pharmaceutical and medical device market, in terms of value, in Europe after Germany. The French pharmaceutical market increased from €53.69B in 2015 to €60.05B in 2019 at a Compound Annual Growth Rate (CAGR) of 2.84%. In terms of US Dollars, the market increased from $59.54B in 2013 to $67.25B in 2020 at a CAGR of 3.09%. It is forecast to reach about $82.02B in 2025. The changing demographics, chronic and lifestyle diseases, incentives for innovation, universal health coverage, and early access to innovative medicines are the main factors driving the growth of the French pharmaceutical market.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in France, and includes:
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Bayer, Pfizer, Sanofi, Viatris, and Servier
  • Profiles and SWOT analyses of the major players in the medical device market: Abbott, Medtronic, Roche Diagnostics, EssilorLuxottica, and Air Liquide
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact, and developments in healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the French healthcare market
Reasons to Buy

This report will enhance your decision-making capability by allowing you to:
  • Develop business strategies by understanding the trends shaping and driving France’s healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact France’s healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
Note: Product cover images may vary from those shown
1. Table of Contents
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Executive Summary
2.2 Key Highlights - Facts about the French Healthcare Market
2.3 Key Highlights: Healthcare Startups in France
2.4 Key Events: French Healthcare Timeline, 2015-2021
2.5 Key Events: French Pharmaceutical Market
2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020
2.7 Key Events: Mergers and Acquisitions
2.8 Country Profile, France, 2020

3. Overview of Pharmaceutical Market
3.1 Pharmaceutical Market - Overview
3.2 Pharmaceutical Market - Exports
3.3 Pharmaceutical Market - Imports
3.4 Pharmaceutical Market - Supply Channels, France
3.5 Pharmaceutical Market - Market Segments
3.6 Major Therapeutic Areas, France
3.7 COVID-19 Epidemiology, France
3.8 COVID-19 Impact and Developments in the Healthcare Market, France
3.9 COVID-19 Clinical Trials Landscape, France
3.10 Pharmaceutical Market - Major Players

4. Overview of Medical Devices Market
4.1 Medical Device Market - Overview
4.2 Medical Devices Market - Major Players

5. Pharmaceutical and Medical Devices Market - Drivers and Barriers
5.1 Drivers
5.2 Barriers

6. Deal Analysis
6.1 Deal Analysis: Pharmaceutical Market, France, 2020-2021
6.2 Deal Analysis: Medical Device Market, France, 2020-2021

7. HealthTech Landscape
7.1 HealthTech Landscape, France
7.2 HealthTech Deals Landscape, France
7.3 Key HealthTech Deals, France
7.4 Adoption of Technology in Healthcare, France
7.5 Key Developments: HealthTech Against COVID-19 Crisis, France
7.6 Regulatory Scenario Covering Use of Technology in Healthcare, France
7.7 HealthTech Landscape: Benefits and Risks, France

8. Market Access
8.1 Overview of Healthcare System, France
8.2 Reimbursement of Medicinal Products, France
8.3 Reimbursement of Medical Devices, France
8.4 Overview of Insurance Providers, France
8.5 Healthcare Spending and Medicine Price Index, France
8.6 Pricing Policies, France
8.7 Regulatory Landscape, France
8.7.1 Overview of Regulatory Agencies
8.7.2 Marketing Authorization for Pharmaceutical Products, France
8.7.3 Marketing Authorization for Medical Devices, France
8.7.4 Intellectual Property Rights, Patent, France
8.7.5 Intellectual Property Rights, Trademark, France
8.7.6 Clinical Trial Regulation, France
8.7.7 Pharmaceutical Clinical Trials Landscape, France
8.7.8 Medical Devices Clinical Trials Landscape, France
8.7.9 Pharmaceutical Export and Import, France
8.7.10 Pharmaceutical Advertisement Regulations, France
8.7.11 Pharmaceutical Establishment Regulations, France
8.6.12 Pharmacy Regulations, France
8.7.13 Labeling and Packaging Regulations, France

9. Country Healthcare Landscape
9.1 French Healthcare Policy Highlights
9.2 Healthcare Facilities, France
9.3 Healthcare Parameters, France
9.4 Life Expectancy and Immunization Rate, France
9.5 Environmental Health, France
9.6 Healthcare Personnel, France
9.7 Disease Burden, France
9.8 Healthcare Expenditure, France
10 Trade Associations, France

11 Trade Fairs, France

12 Opportunities and Challenges

13 Appendix
13.1 Research Methodology
13.1.1 Coverage
13.1.2 Secondary Research
13.1.3 Forecasts
13.2 Bibliography
13.3 About the Publisher
13.4 Contact Us
13.5 Disclaimer

List of Tables
Table 1: Approved Biosimilars, EU, 2020-2021
Table 2: Top Five Therapeutic Areas by Annual Revenue (%), France, 2019
Table 3: COVID-19 Indicators (Number of Cases), Global and France, 2020-2021
Table 4: COVID-19-Related Travel Restrictions, France, 2020-2021
Table 5: COVID-19 Vaccines Authorized, France, 2020-2021
Table 6: COVID-19 Vaccines Under Evaluation, France, 2021
Table 7: COVID-19 IVD Products (June ‘20- June ‘21), France, 2020-2021
Table 8: Medical Device Market, France, Major Segments ($B), 2020
Table 9: General Surgery Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020
Table 10: Cardiovascular Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020
Table 11: Wound Care Management Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020
Table 12: Orthopedic Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020
Table 13: Anesthesia and Respiratory Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020
Table 14: Actual Clinical Benefit Levels, France, 2021
Table 15: Clinical Added Value Levels, France, 2021
Table 16: Reimbursement Rates for Medical Procedures and Services Covered by Health Insurance Schemes, France, 2021
Table 17: Wholesalers-distributors Margin, France, 2020
Table 18: Patent Fees, France, 2021
Table 19: Trademark Fees, France, 2021
Table 20: Outer Packaging of Solid Oral Forms, France, 2021
Table 21: Recommendations Specific to Small Packaging, France, 2021
Table 22: Primary Packaging of Solid Oral Forms, France, 2021
Table 23: Recommendations Specific to Small Blister Packs, France, 2021

List of Figures
Table 1: Pharmaceutical Market, France, Revenue ($B and €B), 2013-2020
Table 2: Medical Devices Market, France, Revenue ($B), 2015-2020
Table 3: Healthcare Startups in France, 2021
Table 4: Number of Deals (2019-2020)
Table 5: 2019-2020 Deal Overview by Region
Table 6: Country Profile, France, 2020
Table 7: Pharmaceutical Market, France, Revenue ($B and €B), 2013-2020
Table 8: Pharmaceutical Market, France, Revenue Forecast ($B and €B), 2021-2025
Table 9: Pharmaceutical Exports ($B), France, 2013-2020
Table 10: Top Export Partners, France, 2020
Table 11: Pharmaceutical Imports ($B), France, 2013-2020
Table 12: Top Import Partners, France, 2020
Table 13: Pharmaceutical Supply Channel, France, 2019
Table 14: % Share of Generics by Value, France, 2019
Table 15: % Share of Generics by Volume, France, 2019
Table 16: Marketing Authorizations (MA) for Generic Medicines, France, 2015-2019
Table 17: Health Competitiveness Clusters, France, 2021
Table 18: OTC Market, France, Revenue ($B), 2013-2020
Table 19: OTC Market by Drug Category, France, Revenue ($M), 2020
Table 20: Top Five Therapeutic Areas by Annual Revenue (%), France, 2019
Table 21: COVID-19 Cases, France, 2020-2021
Table 22: COVID-19 Deaths, France, 2020-2021
Table 23: COVID-19 Fiscal Stimulus Timeline, France, 2020-2021
Table 24: Vaccine Doses Administered per 1,000 People, France, 2021
Table 25: COVID-19 Clinical Trials Count by Phase, France, 2020-2021
Table 26: COVID-19 Clinical Trials Count by Trial Status, France, 2020-2021
Table 27: Top Five COVID-19 Clinical Trials Sponsors by Trial Count, France, 2020-2021
Table 28: Medical Devices Market, France, Revenue ($B), 2015-2020
Table 29: Medical Devices Market, France, Revenue Forecast ($B), 2021-2025
Table 30: Medical Device Market, France, Major Segments (%), 2020
Table 31: General Surgery Market, France, Revenue ($B), 2017-2025
Table 32: General Surgery Market, France, Market Share of Major Players (%), 2020
Table 33: Cardiovascular Devices Market, France, Revenue ($B), 2017-2025
Table 34: Cardiovascular Devices Market, France, Market Share of Major Players (%), 2020
Table 35: Wound Care Management Market, France, Revenue ($B), 2017-2025
Table 36: Wound Care Management Market, France, Market Share of Major Players (%), 2020
Table 37: Orthopedic Devices Market, France, Revenue ($B), 2017-2025
Table 38: Orthopedic Devices Market, France, Market Share of Major Players (%), 2020
Table 39: Anesthesia and Respiratory Devices Market, France, Revenue ($B), 2017-2025
Table 40: Anesthesia and Respiratory Devices Market, France, Market Share of Major Players (%), 2020
Table 41: Diagnostics Market, France, Revenue ($B), 2015-2020
Table 42: Diagnostics Market, France, Revenue Forecast ($B), 2021-2025
Table 43: Medical Devices Market, Revenue ($B) of Major Companies, France, 2020
Table 44: Deal Value and Deal Count, Pharmaceutical Market, France, 2020-2021
Table 45: Deal Value and Deal Count Sub-types, Pharmaceutical Market, France, 2020-2021
Table 46: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, France, 2020-2021
Table 47: Top Five Therapy Areas by Deal Value and Deal Count, Pharmaceutical Market, France, 2020-2021
Table 48: M&A Deals by Therapy Area, Pharmaceutical Market, France, 2020-2021 (by Value ($M) and by Number)
Table 49: VC Deals by Therapy Area, Pharmaceutical Market, France, 2020-2021 (by Value ($M) and by Number)
Table 50: PE Deals by Therapy Area, Pharmaceutical Market, France, 2020-2021 (by Value ($M) and by Number)
Table 51: Medical Devices Market Deals by Deal Value ($M), France, 2020-2021
Table 52: Medical Devices Market Deals by Deal Count, France, 2020-2021
Table 53: Medical Devices Market Deals Share by Deal Value, France, 2020-2021
Table 54: Medical Devices Market Deals Share by Deal Count, France, 2020-2021
Table 55: Top Five Therapy Area by Deal Value ($M), Medical Devices Market, France, 2020-2021
Table 56: Top Five Therapy Area by Deal Count, Medical Devices Market, France, 2020-2021
Table 57: M&A Deals by Therapy Area, Medical Devices Market, France, 2020-2021 (by Value ($M) and by Number)
Table 58: VC Deals by Therapy Area, Medical Devices Market, France, 2020-2021 (by Value ($M) and by Number)
Table 59: Number of Products in Development and Marketed by French HealthTech and Purposes, France, 2020
Table 60: Adoption of eHealth Technologies, France, 2020
Table 61: Deal Value ($B), HealthTech, France, 2020-2021
Table 62: Deal Count (No. of Deals), HealthTech, France, 2020-2021
Table 63: Type of Products Developed by HealthTech Companies Against COVID-19, France, 2020
Table 64: Health Innovation Coalition Projects, France, 2020
Table 65: Organization of the Health System, France, 2020
Table 66: Reimbursement of Medicinal Products, France, 2020
Table 67: Reimbursement of Medical Devices, France, 2021
Note: Product cover images may vary from those shown
France has a mature healthcare market, based on its high healthcare expenditure and pharmaceutical production. The increasingly elderly population is expected to drive the growth of the pharmaceutical market; however, an increasing focus on generics to reduce healthcare expenditure will balance this out.

The French pharmaceutical market was valued at $48.9 billion in 2008 and an estimated $45.9 billion in 2013. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 0.7% from approximately $46.2 billion in 2014 to $48.2 billion in 2020.

The public health insurance system was established in 1945, and by 2011, approximately 97% of the population was covered under Statutory Health Insurance (SHI), divided into three main schemes: general, agriculture, and non-salaried and non-farming (World Bank, 2014p). This universal healthcare coverage is expected to continue to drive the French pharmaceutical market. The increasingly elderly population is also fueling pharmaceutical market growth, accounting for 17.6% of the total population in 2013 and expected to increase at a CAGR of 1.5% to 19.7% by 2020 (INSEE, 2014f).

The government is focusing on the use of generics as a cost-containment tool to reduce healthcare expenditure. It introduced a scheme in September 2012 to increase the use of generic drugs, under which patients who agree to generic substitution will not be required to pay for their drugs. The substitution rate increased from 71% to 84% in one year as a result: a cost saving of approximately €200m ($270m) (Thomson, et al., 2013). In 2008, generic drugs accounted for 9.4% of the pharmaceutical market in terms of value and 21.7% in terms of volume, increasing to an estimated 15.3% and 27.7% respectively in 2013 (ANSM, 2013). However, this is expected to act as a barrier to the growth of the pharmaceutical market.

The French medical device market was valued at $12.7 billion, which increased to $15.5 billion in 2013. It is projected to grow at a CAGR of 5.1% from $16.2 billion in 2014 to $21.8 billion in 2020. In 2013, In Vitro Diagnostics (IVD) accounted for 15.3% of the overall medical device market, followed by cardiovascular devices (11.4%), ophthalmic devices (10.7%), orthopedic devices (8.4%) and hospital supplies (7.4%).
Note: Product cover images may vary from those shown
Adroll
adroll